⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 15, 2024

Supplementary Figure S3 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Tanya B. Dorff Lisa G. Horvath Karen A. Autio Alice Bernard‐Tessier Matthew B. Rettig Jean‐Pascal Machiels Mehmet Asım Bilen Martijn P. Lolkema Nabil Adra Sylvie Rottey Richard Greil Nobuaki Matsubara Daniel S.W. Tan Alvin Wong Hiroji Uemura Charlotte Lemech Johannes Meran Youfei Yu Mukul Minocha Mason McComb Hweixian Leong Penny Vinita Gupta Xuguang Hu Gabor Jurida Hosein Kouros‐Mehr Margit M. Janát‐Amsbury Tobias Eggert Ben Tran

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Duration of PSA response in dose expansion

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dorff et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2aeb6db64358766d83c https://doi.org/10.1158/1078-0432.25603408

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024
2Supplementary Figure S2 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024
3Supplementary Figure S2 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024
4Supplementary Figure S4 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024
5Supplementary Figure S4 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024

Supplementary Figure S5 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024
Supplementary Figure S5 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024
Data from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer2024